Literature DB >> 10466764

Tumour vasculature as a target for cancer therapy.

D J Chaplin1, G J Dougherty.   

Abstract

Entities:  

Mesh：

Year:  1999        PMID： 10466764

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  26 in total

1.  Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.

Authors:  Simon P Robinson; Tammy L Kalber; Franklyn A Howe; Dominick J O McIntyre; John R Griffiths; David C Blakey; Lynsey Whittaker; Anderson J Ryan; John C Waterton
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

Review 2.  The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.

Authors:  Dietmar W Siemann
Journal:  Cancer Treat Rev       Date:  2010-06-08       Impact factor: 12.111

3.  Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy.

Authors:  Michael Kragh; Bjørn Quistorff; Michael R Horsman; Paul E G Kristjansen
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

Review 4.  An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications.

Authors:  Marlein Miranda Cona; Peter de Witte; Alfons Verbruggen; Yicheng Ni
Journal:  World J Methodol       Date:  2013-12-26

Review 5.  A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).

Authors:  Dietmar W Siemann; David J Chaplin; Patricia A Walicke
Journal:  Expert Opin Investig Drugs       Date:  2009-02       Impact factor: 6.206

6.  The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts.

Authors:  Tracy E Strecker; Samuel O Odutola; Ramona Lopez; Morgan S Cooper; Justin K Tidmore; Amanda K Charlton-Sevcik; Li Li; Matthew T MacDonough; Mallinath B Hadimani; Anjan Ghatak; Li Liu; David J Chaplin; Ralph P Mason; Kevin G Pinney; Mary Lynn Trawick
Journal:  Cancer Lett       Date:  2015-09-01       Impact factor: 8.679

7.  Monitoring the treatment efficacy of the vascular disrupting agent CA4P.

Authors:  Beth A Salmon; Howard W Salmon; Dietmar W Siemann
Journal:  Eur J Cancer       Date:  2007-04-23       Impact factor: 9.162

8.  Halichondrin B amide acts as tubulin binding agent to exhibit anti-tumor efficacy in hematologic cancers.

Authors:  Ying-Chun Li; Rong Zhang; Ying Yang; Jia Li; Ke Zhu; Kun Yao; Zhuo-Gang Liu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

9.  The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death.

Authors:  Chryso Kanthou; Olga Greco; Anna Stratford; Ian Cook; Richard Knight; Omar Benzakour; Gillian Tozer
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

10.  Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.

Authors:  M B Jameson; P I Thompson; B C Baguley; B D Evans; V J Harvey; D J Porter; M R McCrystal; M Small; K Bellenger; L Gumbrell; G W Halbert; P Kestell
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.